nach oben

Endocrine

Erschienen in:

18.03.2021 | COVID-19 | Review Zur Zeit gratis

Hypovitaminosis D and the endocrine phenotype of COVID-19

verfasst von: Andrea Giustina

Erschienen in: Endocrine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Vitamin D and its deficiency have recently been suspected to be involved in increased susceptibility and negative outcomes of COVID-19. This assumption was based on the well known immunomodulatory actions of vitamin D and on the consistent finding of low levels of 25 hydroxyvitamin D (25OHD) in hospitalized patients with COVID-19. Moreover, several studies reported a correlation between 25OHD levels and different clinical outcomes of the disease.

Aim

Aim of the current review was to approach the topic of vitamin D and COVID-19 from a different perspective summarizing the data which led to the evidence of the existence of an endocrine phenotype of COVID-19.

Conclusions

This review analyzed in the light of the current knowledge the possibility that several endocrine manifestations of COVID-19 could be holistically interpreted in the context of an inadequate vitamin D status.

A. Gupta, M.V. Madhavan, K. Sehgal, N. Nair, S. Mahajan, T.S. Sehrawat, B. Bikdeli, N. Ahluwalia, J.C. Ausiello, E.Y. Wan, D.E. Freedberg, A.J. Kirtane, S.A. Parikh, M.S. Maurer, A.S. Nordvig, D. Accili, J.M. Bathon, S. Mohan, K.A. Bauer, M.B. Leon, H.M. Krumholz, N. Uriel, M.R. Mehra, M.S.V. Elkind, G.W. Stone, A. Schwartz, D.D. Ho, J.P. Bilezikian, D.W. Landry, Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017–1032 (2020). https://doi.org/10.1038/s41591-020-0968-3CrossRefPubMed

J. Lan et al., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020)PubMed

Ackermann, M. et al., Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. (2020). https://doi.org/10.1056/NEJMoa2015432

M. Puig-Domingo, M. Marazuela, A. Giustina, COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 68, 2–5 (2020). https://doi.org/10.1007/s12020-020-02294-5CrossRefPubMedPubMedCentral

M. Marazuela, A. Giustina, M. Puig-Domingo, Endocrine and metabolic aspects of the COVID-19 pandemic. Rev. Endocr. Metab. Disord. 21, 495–507 (2020). https://doi.org/10.1007/s11154-020-09569-2CrossRefPubMedPubMedCentral

J.P. Bilezikian, D. Bikle, M. Hewison, M. Lazaretti-Castro, A.M. Formenti, A. Gupta, M.V. Madhavan, N. Nair, V. Babalyan, N. Hutchings, N. Napoli, D. Accili, N. Binkley, D.W. Landry, A. Giustina, Mechanisms in endocrinology: vitamin D and COVID-19. Eur. J. Endocrinol. 183, R133–R147 (2020). https://doi.org/10.1530/EJE-20-0665CrossRefPubMed

M.L. Brandi, A. Giustina, Sexual dimorphism of coronavirus 19 morbidity and lethality. Trends Endocrinol. Metab. 31, 918–927 (2020). https://doi.org/10.1016/j.tem.2020.09.003CrossRefPubMedPubMedCentral

A. Giustina, A.M. Formenti, Preventing a covid-19 pandemic Can high prevalence of severe hypovitaminosis D play a role in the high impact of Covid infection in Italy? BMJ 368, m810 (2020)

F. Rubino, S.A. Amiel, P. Zimmet, G. Alberti, S. Bornstein, R.H. Eckel, G. Mingrone, B. Boehm, M.E. Cooper, Z. Chai, S. Del Prato, L. Ji, D. Hopkins, W.H. Herman, K. Khunti, J.C. Mbanya, E. Renard, New-onset diabetes in Covid-19. N. Engl. J. Med. 383, 789–790 (2020). https://doi.org/10.1056/NEJMc2018688CrossRefPubMed

10.

M.M. Lima-Martínez, C. Carrera Boada, M.D. Madera-Silva, W. Marín, M. Contreras, COVID-19 and diabetes: a bidirectional relationship. Clin. Investig. Arterioscler. S0214-9168, 30105–4 (2020). https://doi.org/10.1016/j.arteri.2020.10.001CrossRef

11.

M. Martins, J.M. Boavida, J.F. Raposo, F. Froes, B. Nunes, R.T. Ribeiro, M.P. Macedo, C. Penha-Gonçalves, Diabetes hinders community-acquired pneumonia outcomes in hospitalized patients. BMJ Open Diabetes Res. Care 4, e000181 (2016). https://doi.org/10.1136/bmjdrc-2015-000181CrossRefPubMedPubMedCentral

12.

M. Apicella, M.C. Campopiano, M. Mantuano, L. Mazoni, A. Coppelli, S. Del Prato, COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 8, 782–792 (2020). https://doi.org/10.1016/S2213-8587(20)30238-2CrossRefPubMedPubMedCentral

13.

B. Cariou, S. Hadjadj, M. Wargny, M. Pichelin, A. Al-Salameh, I. Allix et al., Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63, 1500–1515 (2020)PubMedPubMedCentral

14.

A. Corcillo, S. Cohen, A. Li, J. Crane, D. Kariyawasam, J. Karalliedde, Diabetic retinopathy is independently associated with increased risk of intubation: a single centre cohort study of patients with diabetes hospitalised with COVID-19. Diabetes Res. Clin. Pract. 108529 (2020). https://doi.org/10.1016/j.diabres.2020.108529

15.

L.M. Donini, L. Busetto, J.M. Bauer, S. Bischoff, Y. Boirie, T. Cederholm, A.J. Cruz-Jentoft, D. Dicker, G. Frühbeck, A. Giustina, M.C. Gonzalez, H.S. Han, S.B. Heymsfield, T. Higashiguchi, A. Laviano, A. Lenzi, E. Parrinello, E. Poggiogalle, C.M. Prado, J.S. Rodriguez, Y. Rolland, F. Santini, M. Siervo, F. Tecilazich, R. Vettor, J. Yu, M. Zamboni, R. Barazzoni, Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin. Nutr. 39, 2368–2388 (2020). https://doi.org/10.1016/j.clnu.2019.11.024CrossRefPubMed

16.

C. Welch, C. Greig, T. Masud, D. Wilson, T.A. Jackson, COVID-19 and acute sarcopenia. Aging Dis. 11, 1345–1351 (2020). https://doi.org/10.14336/AD.2020.1014CrossRefPubMedPubMedCentral

17.

A. Simonnet, M. Chetboun, J. Poissy, V. Raverdy, J. Noulette, A. Duhamel et al., High prevalence f obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (2020). https://doi.org/10.1002/oby.22831

18.

Y. Huang, Y. Lu, Y.M. Huang, M. Wang, W. Ling, Y. Sui, H.L. Zhao, Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism 113, 154378 (2020). https://doi.org/10.1016/j.metabol.2020.154378CrossRefPubMedPubMedCentral

19.

M.V. Davi’, L. Dalle Carbonare, A. Giustina, M. Ferrari, A. Frigo, V. Lo Cascio, G. Francia, Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159, 533–540 (2008). https://doi.org/10.1530/EJE-08-0442CrossRefPubMed

20.

J.M. Brock, A. Billeter, B.P. Müller-Stich, F. Herth, Obesity and the lung: what we know today. Respiration 1–11 (2020). https://doi.org/10.1159/000509735

21.

M. Castellana, E. Conte, A. Cignarelli, S. Perrini, A. Giustina, L. Giovanella, F. Giorgino, P. Trimboli, Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: a systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 21, 5–16 (2020). https://doi.org/10.1007/s11154-019-09514-yCrossRefPubMed

22.

V.J. Vieira-Potter, Inflammation and macrophage modulation in adipose tissues. Cell Microbiol. 16, 1484–1492 (2014). https://doi.org/10.1111/cmi.12336CrossRefPubMed

23.

N. Sattar, I.B. McInnes, J.J.V. McMurray, Obesity is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation 142(1), 4–6 (2020). https://doi.org/10.1161/CIRCULATIONAHA.120.047659CrossRefPubMed

24.

L. di Filippo, A.M. Formenti, M. Doga, E. Pedone, P. Rovere-Querini, A. Giustina, Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease otcomes. J. Clin. Endocrinol. Metab. dgaa738 (2020). https://doi.org/10.1210/clinem/dgaa738

25.

S. Frara, M. Losa, M. Doga, A.M. Formenti, P. Mortini, G. Mazziotti, A. Giustina, High prevalence of radiological vertebral fractures in patients with TSH-secreting pituitary adenoma. J. Endocr. Soc. 2, 1089–1099 (2018). https://doi.org/10.1210/js.2018-00091CrossRefPubMedPubMedCentral

26.

A.M. Formenti, F. Tecilazich, R. Giubbini, A. Giustina, Risk of vertebral fractures in hypoparathyroidism. Rev. Endocr. Metab. Disord. 20, 295–302 (2019). https://doi.org/10.1007/s11154-019-09507-xCrossRefPubMed

27.

S. Bossoni, L. Chiesa, A. Giustina, Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection. Endocrine 68, 253–254 (2020)PubMedPubMedCentral

28.

L. Di Filippo, A.M. Formenti, P. Rovere-Querini et al., Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68, 475–478 (2020)PubMed

29.

L. di Filippo, A.M. Formenti, M. Doga, S. Frara, P. Rovere-Querini, E. Bosi, M. Carlucci, A. Giustina, Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. Endocrine. 1–5 (2020). https://doi.org/10.1007/s12020-020-02541-9

30.

F. Cappellini, R. Brivio, M. Casati, A. Cavallero, E. Contro, P. Brambilla, Brambilla, Low levels of total and ionized calcium in blood of COVID-19 patients. Clin. Chem. Lab. Med. 58(9), e171–e173 (2020).PubMed

31.

J. Liu, P. Han, J. Wu, J. Gong, D. Tian, Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J. Infect. Public Health 13(9), 1224–1228 (2020). https://doi.org/10.1016/j.jiph.2020.05.029CrossRefPubMedPubMedCentral

32.

J.K. Sun, W.H. Zhang, L. Zou et al., Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging 12(12), 11287–11295 (2020). https://doi.org/10.18632/aging.103526CrossRefPubMedPubMedCentral

33.

J.K. Millet et al., Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology 517, 3–8 (2018)PubMed

34.

M.R. Straus et al., Ca²⁺ ions promote fusion of Middle East respiratory syndrome coronavirus with host cells and increase infectivity. J. Virol. https://doi.org/10.1128/JVI.00426-20 (2020)

35.

L. Nathan et al., Calcium ions directly interact with the Ebola virus fusion peptide to promote structure-function changes that enhance infection. ACS Infect. Dis. 6, 250–260 (2020)PubMed

36.

C.M. Booth et al., Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 289, 2801–2809 (2003)PubMed

37.

T.M. Uyeki et al., Clinical management of Ebola virus disease in the United States and Europe. N. Engl. J. Med. 374, 636–646 (2016)PubMedPubMedCentral

38.

G. Mazziotti, A.M. Formenti, R.A. Adler, J.P. Bilezikian, A. Grossman, E. Sbardella, S. Minisola, A. Giustina, Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54, 603–611 (2016). https://doi.org/10.1007/s12020-016-1146-8CrossRefPubMed

39.

R. Bouillon, C. Marcocci, G. Carmeliet et al., Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr. Rev. 40, 1109–1151 (2019)PubMed

40.

C.T. Sempos, A.C. Heijboer, D.D. Bikle, J. Bollerslev, R. Bouillon, P.M. Brannon, H.F. DeLuca, G. Jones, C.F. Munns, J.P. Bilezikian, A. Giustina, N. Binkley, Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. Br. J. Clin. Pharmacol. 84, 2194–2207 (2018). https://doi.org/10.1111/bcp.13652CrossRefPubMedPubMedCentral

41.

D.O. Meltzer, T.J. Best, H. Zhang, T. Vokes, V. Arora, J. Solway, Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw. Open 3, e2019722 (2020). https://doi.org/10.1001/jamanetworkopen.2020.19722CrossRefPubMedPubMedCentral

42.

N. Hutchings, V. Babalyan, S. Baghdasaryan, M. Qefoyan, N. Sargsyants, E. Aghajanova, A. Martirosyan, R. Harutyunyan, O. Lesnyak, A.M. Formenti, A. Giustina, J.P. Bilezikian, Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. Endocrine (2021). https://doi.org/10.1007/s12020-020-02597-7

43.

L.L. Benskin, A basic review of the preliminary evidence that COVID-19 risk and severity is increased in vitamin D deficiency. Front. Public Health 8, 513 (2020). https://doi.org/10.3389/fpubh.2020.00513CrossRefPubMedPubMedCentral

44.

D. Ferrari, M. Locatelli, M. Briguglio, G. Lombardi, Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity? Cell Biochem. Funct. (2020). https://doi.org/10.1002/cbf.3597

45.

N. Hutchings, V. Babalyan, A. Heijboer et al., Vitamin D insufficiency is widespread in Armenia. ASBMR 2020 Annual meeting virtual event Poster Sessions, Presentation Number: P-592 www.asbmr.org. Poster Presentation (American Society for Bone and Mineral Research Annual Meeting, 2020)

46.

E. Merzon, D. Tworowski, A. Gorohovski et al., Low plasma 25(OH) vitamin D level is associated with increased risk of COVID19 infection: an Israeli population-based study. FEBS J. 17, 3693–3702 (2020)

47.

Z. Maghbooli, M.A. Sahraian, M. Ebrahimi et al., Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS ONE 15(9), e0239799 (2020)PubMedPubMedCentral

48.

H.W. Kaufman, J.K. Niles, M.H. Kroll, C. Bi, M.F. Holick, SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS ONE 15(9), e0239252 (2020)PubMedPubMedCentral

49.

C.E. Hastie, D.F. Mackay, F. Ho et al., Vitamin D concentrations and COVID-19 infection in UKbiobank. Diabetes Metab. Syndr. 14(4), 561–56 (2020)PubMedPubMedCentral

50.

D. De Smet, K. De Smet, P. Herroelen, S. Gryspeerdt, G.A. Martens, Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality. Am. J. Clin. Pathol. aqaa252 (2020). https://doi.org/10.1093/ajcp/aqaa252

51.

M. Entrenas Castillo, L.M. Entrenas Costa, J.M. Vaquero Barrios, J.F. Alcalá Díaz, J. López Miranda, R. Bouillon, J.M. Quesada Gomez, “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”. J. Steroid Biochem. Mol. Biol. 203, 105751 (2020). https://doi.org/10.1016/j.jsbmb.2020.105751CrossRefPubMedPubMedCentral

52.

A. Giustina, R.A. Adler, N. Binkley, J. Bollerslev, R. Bouillon, B. Dawson-Hughes, P.R. Ebeling, D. Feldman, A.M. Formenti, M. Lazaretti-Castro, C. Marcocci, R. Rizzoli, C.T. Sempos, J.P. Bilezikian, Consensus statement from 2^nd international conference on controversies in vitamin D. Rev. Endocr. Metab. Disord. 21, 89–116 (2020). https://doi.org/10.1007/s11154-019-09532-wCrossRefPubMedPubMedCentral

53.

G. Isaia, R. Giorgino, G.B. Rini, M. Bevilacqua, D. Maugeri, S. Adami, Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos. Int. 14, 577–582 (2003)

54.

A. Giustina, R. Bouillon, N. Binkley, C. Sempos, R.A. Adler, J. Bollerslev, B. Dawson-Hughes, P.R. Ebeling, D. Feldman, A. Heijboer, G. Jones, C.S. Kovacs, M. Lazaretti-Castro, P. Lips, C. Marcocci, S. Minisola, N. Napoli, R. Rizzoli, R. Scragg, J.H. White, A.M. Formenti, J.P. Bilezikian, Controversies in vitamin D: a statement from the third international conference. JBMR 4, e10417 (2020). https://doi.org/10.1002/jbm4.10417CrossRef

55.

A. Giustina, R.A. Adler, N. Binkley et al., Controversies in vitamin D: summary statement from an international conference. J. Clin. Endocrinol. Metab. 104, 234–240 (2019)PubMed

56.

P.B. Whittemore, COVID-19 fatalities, latitude, sunlight, and vitamin D. Am. J. Infect. Control 48(9), 1042–1044 (2020)PubMedPubMedCentral

57.

A.R. Martineau, D.A. Jolliffe, R.L. Hooper et al., Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356, i6583 (2017)PubMedPubMedCentral

58.

J.A. Grace, S. Klein, C.B. Herath et al., Activation of the MAS receptor by angiotensin-(1–7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 145(4), 874–884 (2013)PubMed

59.

G. Mazziotti, F. Maffezzoni, A. Giustina, Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy? Endocrine 52, 183–186 (2016). https://doi.org/10.1007/s12020-016-0890-0CrossRefPubMed

60.

M.M. Speeckaert, J.R. Delanghe, Association between low vitamin D and COVID-19: don’t forget the vitamin D binding protein. Aging Clin. Exp. Res. 32(7), 1207–1208 (2020)PubMedPubMedCentral

61.

M.M. Speeckaert, R. Speeckaert, N. van Geel, J.R. Delanghe, Vitamin D binding protein: a multifunctional protein of clinical importance. Adv. Clin. Chem. 63, 1–57 (2014)PubMed

62.

L. Du, J. Zhou, J. Zhang et al., Actin filament reorganization is a key step in lung inflammation induced by systemic inflammatory response syndrome. Am. J. Respir. Cell Mol. Biol. 47(5), 597–603 (2012)PubMed

63.

R.R. Kew, The vitamin D binding protein and inflammatory injury: a mediator or sentinel of tissue damage? Front. Endocrinol. 10, 470 (2019)

64.

L.E. Gralinski, T.P. Sheahan, T.E. Morrison et al., Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9(5), 1–15 (2018)

65.

P. Mehta, D.F. McAuley, M. Brown et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229), 1033–1034 (2020)PubMedPubMedCentral

66.

X. Chen, B. Zhao, Y. Qu et al., Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis. (2020). https://doi.org/10.1093/cid/ciaa449

67.

D.D. Bikle, J. Schwartz, Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front. Endocrinol. 10, 317 (2019)

68.

N. Vyas, S.J. Kurian, D. Bagchi et al., Vitamin D in prevention and treatment of COVID-19: current perspective and future prospects. J. Am. Coll. Nutr. 1–14 (2020). https://doi.org/10.1080/07315724.2020.1806758

69.

K. Amrein, B. Venkatesh, Vitamin D and the critically ill patient. Curr. Opin. Clin. Nutr. Metab. Care 15(2), 188–193 (2012)PubMed

70.

K.B. Christopher, Vitamin D and critical illness outcomes. Curr. Opin. Crit. Care 22(4), 332–338 (2016)PubMed

71.

J. MacLaughlin, M.F. Holick, Aging decreases the capacity of human skin to produce vitamin D3. J. Clin. Investig. 76(4), 1536–8 (1985)PubMedPubMedCentral

72.

S. Garcovich, G. Colloca, P. Sollena, B. Andrea, L. Balducci, W.C. Cho et al., Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 8(5), 643–661 (2017)PubMedPubMedCentral

73.

A.A. Ginde, M.C. Liu, C.A. Camargo, Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch. Intern. Med. 169(6), 626–632 (2009)PubMedPubMedCentral

74.

J.C. Gallagher, Vitamin D and aging. Endocrinol. Metab. Clin. N. Am. 42(2), 319–332 (2013)

75.

T. Hagenau, R. Vest, T.N. Gissel, C.S. Poulsen, M. Erlandsen, L. Mosekilde et al., Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos. Int. 20(1), 133–140 (2009)PubMed

76.

K.D. Cashman, S. Muldowney, B. McNulty, A. Nugent, A.P. FitzGerald, M. Kiely et al., Vitamin D status of Irish adults: findings from the National Adult Nutrition Survey. Br. J. Nutr. 109(7), 1248–1256 (2013)PubMed

77.

P. Lips, Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 22(4), 477–501 (2001)PubMed

78.

A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton et al., The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96(1), 53–58 (2011)PubMed

79.

B. Dawson-Hughes, A. Mithal, J.-P. Bonjour, S. Boonen, P. Burckhardt, G.E.-H. Fuleihan et al., IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int 21(7), 1151–1154 (2010)PubMed

80.

E. Orwoll et al., Vitamin D deficiency in older men. J. Clin. Endocrinol. Metab. 94, 1214–1222 (2009)PubMedPubMedCentral

81.

A.M. Formenti, E. Pedone, L. di Filippo, F.M. Ulivieri, A. Giustina, Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 70, 203–205 (2020). https://doi.org/10.1007/s12020-020-02500-4CrossRefPubMed

82.

P.R. Ebeling, R.A. Adler, G. Jones et al., Management of endocrine disease: therapeutics of vitamin D. Eur. J. Endocrinol. 179, R239–R259 (2018)PubMed

83.

E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007). https://doi.org/10.1056/NEJMra067395CrossRefPubMed

84.

M. Doga, S. Bonadonna, A. Burattin, R. Carpinteri, F. Manelli, A. Giustina, Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis. Front. Horm. Res. 30, 150–164 (2002). https://doi.org/10.1159/000061082CrossRefPubMed

85.

P. Pietschmann, G. Schernthaner, W. Woloszczuk, Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 31, 892–895 (1988)PubMed

86.

G. Isaia et al., High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24, 1496 (2001)PubMed

87.

G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). https://doi.org/10.1007/s12020-011-9570-2CrossRefPubMed

88.

K.K. Al Dossari, G. Ahmad, A. Aljowair et al., Association of vitamin d with glycemic control in Saudi patients with type 2 diabetes: a retrospective chart review study in an emerging university hospital. J. Clin. Lab. Anal. 34(2), e23048 (2020). https://doi.org/10.1002/jcla.23048CrossRefPubMed

89.

S. Afzal et al., Low vitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin. Chem. 59, 381–391 (2013)PubMed

90.

A. Tsur et al., Decreased serum concentrations of 25-hydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetes. Diabetes Care 36, 1361–1367 (2013)PubMedPubMedCentral

91.

P. Lemieux et al., Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial. Eur. J. Endocrinol. 181, 287–299 (2019)PubMed

92.

Z. Hu, J. Chen, X. Sun, L. Wang, A. Wang, Efficacy of vitamin D supplementation on glycemic control in type 2 diabetes patients: a meta-analysis of interventional studies. Medicine 98(14), e14970 (2019). https://doi.org/10.1097/MD.0000000000014970CrossRefPubMedPubMedCentral

93.

Y.H. Krul-Poel, M.M. Ter Wee, P. Lips, S. Simsek, Management of endocrine disease: the effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Eur. J. Endocrinol. 176(1), R1–R14 (2017). https://doi.org/10.1530/EJE-16-0391CrossRefPubMed

94.

A.G. Pittas, B. Dawson-Hughes, P. Sheehan et al., Vitamin D supplementation and prevention of type 2 diabetes. N. Engl. J. Med. 381(6), 520–530 (2019). https://doi.org/10.1056/NEJMoa1900906CrossRefPubMedPubMedCentral

95.

E.G. Price-Haywood, J. Burton, D. Fort, L. Seoane, Hospitalization and mortality among black patients and white patients with Covid-19. N. Engl. J. Med. 382, 2534–2543 (2020). https://doi.org/10.1056/NEJMsa2011686CrossRefPubMed

96.

S.K. Singh, R. Jain, S. Singh, Vitamin D deficiency in patients with diabetes and COVID- 19 infection. Diabetes Metab. Syndr. 87, 1033–1035 (2020). https://doi.org/10.1016/j.dsx.2020.06.071CrossRef

97.

F. Tecilazich, A.M. Formenti, A. Giustina, Role of vitamin D in diabetic retinopathy: pathophysiological and clinical aspects. Rev. Endocr. Metab. Disord. 1–13 (2020). https://doi.org/10.1007/s11154-020-09575-4

98.

H. Kaur et al., Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 34, 1400–1402 (2011)PubMedPubMedCentral

99.

M. Long et al., Glycated hemoglobin A1C and vitamin D and their association with diabetic retinopathy severity. Nutr. Diabetes 7, e281 (2017)PubMedPubMedCentral

100.

B.A. Luo, F. Gao, L.L. Qin, The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients 9(3), 307 (2017). https://doi.org/10.3390/nu9030307CrossRefPubMedCentral

101.

J. Zhang et al., Relationship between vitamin D deficiency and diabetic retinopathy: a meta-analysis. Can. J. Ophthalmol. 52(Suppl 1), S39–S44 (2017)PubMed

102.

A. Keech et al., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005)PubMed

103.

U. Mutlu et al., Vitamin D and retinal microvascular damage: the Rotterdam Study. Medicine 95, e5477 (2016)PubMedPubMedCentral

104.

P. Jha et al., Low serum vitamin D levels are associated with increased arterial stiffness in youth with type 2 diabetes. Diabetes Care 38, 1551–1557 (2015)PubMedPubMedCentral

105.

J.A. Sugden et al., Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25, 320–325 (2008)PubMed

106.

S. Munisamy et al., Impaired microvascular endothelial function in vitamin D-deficient diabetic nephropathy patients. J. Cardiovasc. Med. 14, 466–471 (2013)

107.

F. Uberti et al., Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways. J. Clin. Endocrinol. Metab. 99, 1367–1374 (2014)PubMed

108.

M. Pereira-Santos, P.R.F. Costa, A.M.O. Assis, C.A.S.T. Santos, D.B. Santos, Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes. Rev. 16(4), 341–349 (2015)PubMed

109.

A.M. Formenti, A. Dalla Volta, L. di Filippo, A. Berruti, A. Giustina, Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends Endocrinol. Metab. 32(3), 135–158 (2021). https://doi.org/10.1016/j.tem.2020.12.004CrossRefPubMed

110.

S. Monteverdi, R. Pedersini, F. Gallo, F. Maffezzoni, A. Dalla Volta, P. Di Mauro, A. Turla, L. Vassalli, M. Ardine, A.M. Formenti, E.L. Simoncini, A. Giustina, R. Maroldi, V. Amoroso, A. Berruti, The Interaction of Lean Body Mass With Fat Body Mass is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy. JBMR Plus 5(2), e10440 (2020). https://doi.org/10.1002/jbm4.10440CrossRefPubMedPubMedCentral

111.

A. Bassatne, M. Chakhtoura, R. Saad, G.E. Fuleihan, Vitamin D supplementation in obesity and during weight loss: a review of randomized controlled trials. Metabolism 92, 193–205 (2019). https://doi.org/10.1016/j.metabol.2018.12.010CrossRefPubMed

112.

E. Hyppönen, B.J. Boucher, Adiposity, vitamin D requirements, and clinical implications for obesity-related metabolic abnormalities. Nutr. Rev. 76(9), 678–692 (2018). https://doi.org/10.1093/nutrit/nuy034CrossRefPubMed

113.

A.M. Formenti, F. Tecilazich, S. Frara, R. Giubbini, H. De Luca, A. Giustina, Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism. Endocrine 66, 699–700 (2019)PubMed

114.

C.P. Earthman, L.M. Beckman, K. Masodkar, S.D. Sibley, The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J. Obes. 36(3), 387–396 (2012)

115.

C. Ding, D. Gao, J. Wilding, P. Trayhurn, C. Bing, Vitamin D signalling in adipose tissue. Br. J. Nutr. 108(11), 1915–1923 (2012)PubMed

116.

H.K. Biesalski, Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome. Curr. Opin. Clin. Nutr. Metabol. Care (2020). https://doi.org/10.1097/mco.0000000000000700

117.

H.A. Bischoff-Ferrari, T. Dietrich, E.J. Orav, B. Dawson-Hughes, Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am. J. Med. 116(9), 634–639 (2004)PubMed

118.

H.M. Macdonald, I.R. Reid, G.D. Gamble, W.D. Fraser, J.C. Tang, A.D. Wood, 25-hydroxyvitamin D threshold for the effects of vitamin D supplements on bone density: secondary analysis of a randomized controlled trial. J. Bone Miner. Res. 33(8), 1464–1469 (2018)PubMed

119.

I.R. Reid, A.M. Horne, B. Mihov, G.D. Gamble, F. Al-Abuwsi, M. Singh, L. Taylor, S. Fenwick, C.A. Camargo, A.W. Stewart, R. Scragg, Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. J. Intern. Med. 282(5), 452–460 (2017)PubMed

120.

R. Bouillon, N.M. Van Schoor, E. Gielen, S. Boonen, C. Mathieu, D. Vanderschueren, P. Lips, Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J. Clin. Endocrinol. Metab. 98(8), E1283–E1304 (2013)PubMed

121.

R.J. Heikinheimo, J.A. Inkovaara, E.J. Harju, M.V. Haavisto, R.H. Kaarela, J.M. Kataja, A.M. Kokko, L.A. Kolho, S.A. Rajala, Annual injection of vitamin D and fractures of aged bones. Calcif. Tissue Int. 51(2), 105–110 (1992)PubMed

122.

D.P. Trivedi, R. Doll, K.T. Khaw, Effect of four monthly oral vitamin D₃ (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326(7387), 469 (2003)PubMedPubMedCentral

123.

B. Dawson-Hughes, S.S. Harris, E.A. Krall, G.E. Dallal, Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337(10), 670–676 (1997)PubMed

124.

E.R. Larsen, L. Mosekilde, A. Foldspang, Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J. Bone Min. Res. 19(3), 370–378 (2004)

125.

A. Avenell, J.C. Mak, D. O’Connell, Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst. Rev. 2014(4), CD000227 (2014). https://doi.org/10.1002/14651858.CD000227.pub4CrossRefPubMedCentral

126.

B.M. Tang, G.D. Eslick, C. Nowson, C. Smith, A. Bensoussan, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370(9588), 657–666 (2007)PubMed

127.

R. Jiajue, Y. Jiang, X. Qi, Q. Wang, W. Wang, Y. Pei, X. Wang, W. Huang, X. Zheng, Z. Ning, O. Wang, M. Li, X. Xing, W. Yu, L. Xu, W. Xia, Calciotropic hormones and the prevalence of vertebral fractures in chinese postmenopausal women with vitamin D insufficiency: peking vertebral fracture study. Calcif. Tissue Int. 104, 622–630 (2019). https://doi.org/10.1007/s00223-019-00531-2CrossRefPubMed

128.

F. Tecilazich, A.M. Formenti, S. Frara, R. Giubbini, A. Giustina, Treatment of hypoparathyroidism. Best. Pract. Res. Clin. Endocrinol. Metab. 32, 955–964 (2018). https://doi.org/10.1016/j.beem.2018.12.002CrossRefPubMed

129.

S. Chiavistelli, A. Giustina, G. Mazziotti, Parathyroid hormone pulsatility: physiological and clinical aspects. Bone Res. 3, 14049 (2015). https://doi.org/10.1038/boneres.2014.49CrossRefPubMedPubMedCentral

130.

S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E.A. Rosei, D. Valle, N. Iori, J.P. Bilezikian, J.D. Veldhuis, A. Giustina, Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur. J. Endocrinol. 152, 199–205 (2005). https://doi.org/10.1530/eje.1.01841CrossRefPubMed

131.

S.J. Rubin, J.H. Park, E.N. Pearce, M.F. Holick, D. McAneny, J.P. Noordzij, Vitamin D status as a predictor of postoperative hypocalcemia after thyroidectomy. Otolaryngol. Head Neck Surg. 163, 501–507 (2020). https://doi.org/10.1177/0194599820917907CrossRefPubMed

132.

J.L. Hernández, D. Nan, M. Fernandez-Ayala, M. García-Unzueta, M.A. Hernández-Hernández, M. López-Hoyos, P. Muñoz-Cacho, J.M. Olmos, M. Gutiérrez-Cuadra, J.J. Ruiz-Cubillán, J. Crespo, V.M. Martínez-Taboada, Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J. Clin. Endocrinol. Metab. dgaa733 (2020). https://doi.org/10.1210/clinem/dgaa733

133.

V.P. Singh, B. Khatua, B. El-Kurdi, C. Rood, Mechanistic basis and therapeutic relevance of hypocalcemia during severe COVID-19 infection. Endocrine 70(3), 461–462 (2020).PubMed

134.

L. di Filippo, A.M. Formenti, A. Giustina, Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19. Endocrine 70, 463–464 (2020). https://doi.org/10.1007/s12020-020-02525-9CrossRefPubMed

Titel: Hypovitaminosis D and the endocrine phenotype of COVID-19
verfasst von: Andrea Giustina
Publikationsdatum: 18.03.2021
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Endocrine / Ausgabe 1/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02671-8

Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease

Original Article

Thyroid imaging reporting and data system (TIRADS) for ultrasound features of nodules: multicentric retrospective study in China

Original Article

Hyperthermal liquid, spray, and smog may be potential risk factors for recurrent laryngeal nerve thermal injury during thyroid surgeries

Original Article

Hemodynamic changes in neonates born to mothers with Graves’ disease

Original Article

Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study

Original Article

Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism

Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

20.01.2025
Koronare Herzerkrankung
Nachrichten

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

20.01.2025
Chronische Herzinsuffizienz
Nachrichten

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

17.01.2025
Dekubitus
Nachrichten

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hypovitaminosis D and the endocrine phenotype of COVID-19

Abstract

Background

Aim

Conclusions

Weitere Artikel der Ausgabe 1/2021

Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease

Thyroid imaging reporting and data system (TIRADS) for ultrasound features of nodules: multicentric retrospective study in China

Hyperthermal liquid, spray, and smog may be potential risk factors for recurrent laryngeal nerve thermal injury during thyroid surgeries

Hemodynamic changes in neonates born to mothers with Graves’ disease

Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study

Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Background

Aim

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten